Diazabicyclic aryl derivatives as cholinergic receptor modulators
This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemicals substances.
1. A diazabicyclic aryl derivative represented by Formula I
any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein
n is 2; and
A represents a pyridine group;
B represents a phenyl group, optionally substituted with substituents selected from the group consisting of alkyl, cycloalkyl, hydroxyl, alkoxy, cyanoalkyl, halo, trihaloalkyl, trihaloalkoxy, cyano, amino, nitro and —NH(CO)-alkyl; and
L represents —NH(CO)NH—.
2. The diazabicyclic aryl derivative of claim 1 , any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein
B represents a phenyl group, optionally substituted with substituents selected from the group consisting of alkyl, cycloalkyl, hydroxy, alkoxy, cyanoalkyl, halo, trihaloalkyl, trihaloalkoxy, cyano, amino, nitro and —NH(CO)-alkyl.
3. The diazabicyclic aryl derivative of claim 1 , which is
1-[6-(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-pyridin-3-yl]-3-(2-nitro-phenyl)-urea-1-N-oxide;
1-[6-(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-pyridin-3-yl]-3-phenyl-urea;
or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a therapeutically effective amount of an diazabicyclic aryl derivative of claim 1 , any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.